Key Takeaways
- AI-Powered Therapeutics Leap: BigHat Biosciences partners with Johnson & Johnson to fast-track antibody discovery using its ML-guided Milliner™ platform.
- Precision Meets Speed: The collaboration targets multiple complex neuroscience indications with AI-designed antibodies showing improved biophysical functionality.
- Biopharma’s New Era: Marks another major pharma alliance demonstrating how AI platforms are transforming drug design timelines and therapeutic precision.
A Strategic Leap: BigHat Joins Forces with Johnson & Johnson for Neuroscience Innovation
BigHat Biosciences, known for its AI-native approach to protein engineering, announced a major strategic collaboration with Janssen Biotech Inc., a Johnson & Johnson company, focused on developing next-generation antibody therapeutics for neuroscience. By integrating BigHat’s Milliner™ platform with Johnson & Johnson’s discovery and clinical development capabilities, the partnership sets a new benchmark for how AI can be embedded early in biologics R&D to deliver faster and more functionally superior therapeutic candidates.
Inside the Platform: How Milliner™ Is Revolutionizing Antibody Design
At the heart of this collaboration is BigHat’s Milliner™ platform — a full-stack AI/ML system combining high-speed synthetic biology workflows with state-of-the-art machine learning. Unlike traditional methods, Milliner™ uses closed-loop feedback from wet lab experiments to train models in real-time, enabling rapid design–test–learn cycles. This accelerates antibody optimization, supports complex functionality engineering, and significantly lowers the barrier to translating novel biology into safe, effective biologics.
Focus on Neuroscience: Tackling Complexity with AI
The initial focus of the alliance is on advancing novel antibody candidates for neurological disorders — among the most complex and under-addressed therapeutic areas. By combining BigHat’s computational prediction capabilities with Johnson & Johnson’s deep domain expertise, the collaboration aims to develop candidates that demonstrate better specificity, enhanced blood-brain barrier penetration, and reduced immunogenicity — vital for treating conditions like Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.
AI-Powered Biopharma R&D: The Road Ahead
This alliance reflects a broader transformation across biopharma where AI-native platforms are being embedded into discovery and translational research. BigHat’s growing portfolio of partnerships — including Lilly, AbbVie, and now Johnson & Johnson — underscores confidence in its technology stack and strategic direction. As AI reshapes therapeutic pipelines, collaborations like this show how pharma and AI-first biotech can accelerate the timeline from molecule design to clinical readiness — all while improving the probability of success in complex therapeutic spaces.
🔗 Learn more about BigHat Biosciences: www.bighatbio.com
By
